

Original article

Natural killer cells 56^{bright}16⁻ have higher counts in the umbilical cord blood than in the adult peripheral blood



Vinicius Campos de Molla ^{a,b}, Míriam Cristina Rodrigues Barbosa ^a,
Alfredo Mendrone Junior ^b, Matheus Vescovi Gonçalves ^{a,*},
Eliza Kimuraa Fabio Guirao ^a, Mihoko Yamamoto ^a, Celso Arrais-Rodrigues ^{a,b}

^a Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil

^b Hospital 9 de Julho, São Paulo, Brazil

ARTICLE INFO

Article history:

Received 31 January 2022

Accepted 3 July 2022

Available online 19 August 2022

Keywords:

Plasmacytoid dendritic cell

Natural killer cells

Umbilical cord blood

Peripheral blood

ABSTRACT

Introduction and hypothesis: Umbilical cord blood (UCB) is an alternative source of hematopoietic stem cells for allogeneic hematopoietic stem cell transplantation in the absence of a compatible donor. The UCB transplantation has a lower incidence of chronic graft versus host disease (GvHD), but is associated with slower engraftment and slower immune reconstitution, compared to other sources. Dendritic cells (DCs) and Natural Killer cells (NKs) play a central role in the development of GvHD and the graft versus leukemia (GvL) effect, as well as in the control of infectious complications. **Method:** We quantified by multiparametric flow cytometry monocytes, lymphocytes, NK cells, and DCs, including their subsets, in UCB samples from 54 healthy newborns and peripheral blood (PB) from 25 healthy adult volunteers.

Results: In the UCB samples, there were higher counts of NK cells 56^{bright}16⁻ (median 0.024 × 10⁹/L), compared to the PB samples (0.012 × 10⁹/L, *p* < 0.0001), NK 56^{dim}16^{bright} (median 0.446 × 10⁹/L vs. 0.259 × 10⁹/L for PB samples, *p* = 0.001) and plasmacytoid dendritic cells (pDCs, median 0.008 × 10⁹/L for UCB samples vs. 0.006 × 10⁹/L for PB samples, *p* = 0.03). Moreover, non-classic monocyte counts were lower in UCB than in PB (median 0.024 × 10⁹/L vs. 0.051 × 10⁹/L, respectively, *p* < 0.0001).

Conclusion: In conclusion, there were higher counts of NK cells and pDCs and lower counts of non-classic monocytes in UCB than in PB from healthy individuals. These findings might explain the lower incidence and severity of chronic GvHD, although maintaining the GvL effect, in UCB transplant recipients, compared to other stem cell sources.

© 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

In the last few years, allogeneic hematopoietic stem cell transplantation (HSCT) has improved clinical outcomes, with less transplant-related mortality (TRM) and better overall survival (OS).¹ Despite the advance in the knowledge of immune

* Corresponding author at: Universidade Federal de São Paulo (Unifesp), Rua Diogo de Faria, 824, CEP: 04037-002, São Paulo, Brazil.

E-mail address:

<https://doi.org/10.1016/j.htct.2022.07.001>

2531-1379/© 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

reconstitution in HSCT, there are still gaps in this field, such as the mechanisms of immunotolerance, graft-versus-host-disease (GvHD) or graft-versus-leukemia (GvL) effect.²

The umbilical cord blood (UCB) transplant was performed for the first time in 1988.³ The UCB transplant is associated with delayed engraftment, increased risk of infections, greater engraftment failure and worse TRM, compared to bone marrow (BM) and peripheral blood (PB) sources.⁴ However, the UCB transplant usually causes less acute GvHD (aGvHD) and chronic GvHD (cGvHD) with similar rates of leukemia-free survival.⁵ This could be explained by distinctive patterns of immune reconstitution according to the graft source,⁶ regardless of the conditioning regimen.⁷

Dendritic cells (DCs) are antigen-presenting cells, making the connection between innate and adaptive immunity,⁸ as well as coordinating the immune system through activation and stimulation of T and B cells, the tolerance by removal of self-reactive T cells⁹ and the linkage with regulatory T cells.¹⁰ So, the DCs play a key role in the immune system control. In the PB, the DCs are present in two subsets: myeloid (or conventional) DCs (mDCs) and plasmacytoid DCs (pDCs). The pDCs (CD123+CD11c) produce interferon (IFN) I and are implicated in the viral immune response, immune tolerance and memory. At the same time, mDCs (CD123-CD11c+) are responsible for a proinflammatory effect. Each DC subset is flexible *in vivo* and its responses vary according to factors, such as its activation state, the nature of the stimulus received and the inflammatory microenvironment.¹¹ In the immune recovery after the HSCT, the DCs play a relevant role in the aGvHD, cGvHD, GvL and host response to infections,¹² while a poor DC reconstitution is associated with an increased risk of relapse and poor survival.^{13,14}

The NKT cells (NKTs) are T cells that express NK receptors, including NK 1.1 (CD161c) and semi-invariant CD1d-restricted $\alpha\beta$ T-cell receptors (TCRs). There are two types of NKTs: the type I NKT (or iNKT), that expresses the $V\alpha 24-J\alpha 18$, and the type II NKT that expresses TCRs other than the $V\alpha 24-J\alpha 18$.¹⁵

Natural killer cells (NKs) are components of the innate immune system, eliminating tumor and infected cells, promoting cellular lysis in the absence of the HLA class I receptor. The NK cells are categorized as the NK 56^{dim}16^{bright} (90% of NKs in PB), with a predominant cytotoxic effect through the release of granzyme B and perforin, and the NK 56^{bright}16⁻, related to the interferon gamma (INF- γ) and tumor necrosis factor α (TNF- α) secretion.¹⁶ The NKs are the first cells to recover after the HSCT and strongly contribute to the GvL effect, possibly due to the killer-cell immunoglobulin-like receptor (KIR) mismatch.¹⁷ It has been shown that low counts of the NK 56^{bright}16⁻ after the HSCT are associated with a lower survival rate¹⁸ and that KIR mismatches improve survival.¹⁹

To better understand the mechanisms involved in different outcomes in the HSCT using UCB or PB, we compared the composition of immune-related cells in these two HSC sources (monocytes, B lymphocytes, T cells, NK cells and DCs and their subsets) in samples of UCB and PB.

Methods

Population and design

This was a descriptive study. Samples of 54 UCB and 25 PB were collected between September 2015 and July 2017. UCB samples from healthy newborns, with a minimum gestational age of 35 weeks, were collected at the Cellular Therapy Center of the Hospital Sírio Libanês (before freezing). The UCB from neonates with any antenatal risk factors were excluded. The PB samples were collected from healthy adult blood donors at the Hospital São Paulo / UNIFESP Blood Center. The blood donors and pregnant women who agreed to donate the UCB (both ≥ 18 years old), without any documented chronic illness or infectious disease, entered the study. The blood donor volunteers who had received blood transfusion in the last 3 months were excluded.

The study was approved by the local ethics committee of the participating centers and all volunteers (blood donors and mothers) gave their informed consent before entering the study, in accordance with the Declaration of Helsinki.

Cell identification and count by flow cytometry

Fresh EDTA-anticoagulated PB or UCB samples were processed in up to 24 hours after collection. The total number of nucleated cells from the UCB was quantified by the Coulter AcT Diff 2[®] (Beckman Coulter, Brea, USA) and the PB cells, by the Cell Dyn Ruby[®] (Abbott, Illinois, USA), and the erythroblasts were quantified by microscopy to correct the leukocyte count. Leukocytes and subsets were analyzed by flow cytometry.

Cells were stained using an 8-color monoclonal antibodies panel (Table 1): CD16 FITC / CD56+CD4 PE / CD11c PerCP Cy5.5 / CD8+CD19 PC7 / CD123 APC / CD3+CD14 APC-H7/ HLA-DR Pac Blue/ CD45 OC-515, by the stain-lyse-wash method. The reagents were purchased from: Cytognos, Salamanca (CD16, CD56, CD4, CD45), BDB, San Jose, CA (CD11c, CD3, CD14),

Table 1 – Monoclonal antibodies used.

Monoclonal antibody	Company	Clone
FITC		
CD16	Cytognos	3G8
PE		
CD56	Cytognos	C5.9
CD4	Cytognos	Edu-2
PerCP Cy5.5		
CD11c	BD Biosciences	B-ly6
PC7		
CD8	Immunotech	SFCI21Thy2D3
CD19	Immunotech	J3-119
APC		
CD123	Biologend	6H6
APC-H7		
CD3	BD Biosciences	SK7
CD14	BD Biosciences	M ϕ P9
PB		
HLA-DR	Biologend	L243
OC-515		
CD45	Cytognos	GA90




Figure 1–Dot plot graphs of flow cytometry analyses showing gating strategy to natural killer cell identification. NK cells have small size and complexity, strong CD45, are negative for CD3 and HLA-DR and have positive CD56 (A–E). They are further divided into two subpopulations: NK CD56⁺⁺/CD16⁻ and NK CD56⁺/CD16⁺.

Immunotech Brea (CD8), Immunotech Marseille (CD19) and Biolegend, San Diego (HLA-DR, CD123). Data acquisition: 500,000 events for each sample tube were performed using the FACSCANTOII flow cytometer (BDB- San Jose, CA) and the FACSDIVA[®] software (BDB- San Jose, CA) and the Infinicity[®] software (Cytognos, SL) was used for data analysis. The NK cells (CD3⁻, CD19⁻, CD14⁻ and CD56⁺), were classified as NK 56^{bright}16⁻ or NK 56^{dim}16^{bright}. Monocytes (CD45⁺, CD11c⁺ and HLA-DR⁺) were classified as: classic (CD14⁺⁺CD16⁻),

intermediate (CD14⁺⁺CD16⁺) and non-classic (CD14^{dim}CD16⁺). Dendritic cells (HLA-DR⁺⁺, CD3⁻, CD19⁻, CD14⁻ and CD56⁻) were classified as pDC (CD123⁺/CD11c⁻) and mDC (CD123⁻/CD11c⁺⁺) (Figure 1–3).

Statistical methods

The descriptive statistical analysis was reported by using percentages (categorical variables) and ranges and medians




Figure 2–Dot plot graphs of flow cytometry analyses showing gating strategy to natural killer cell identification. NK cells have small size and complexity, strong CD45, are negative for CD3 and HLA-DR and have positive CD56 (A–E). They are further divided into two subpopulations: NK CD56++/CD16- and NK CD56+/CD16+.

(continuous variables). Comparisons between UCB and PB were performed using the Mann-Whitney test. A p -value of $< .05$ was considered significant. The SPSS version 21.0 (SPSS Inc., Chicago, IL) was used for all statistical analyses.

Results

Clinical characteristics

Seventy-nine samples (54 UCB and 25 PB) were obtained. The UCB samples were collected from newborns with a median gestational age of 40 weeks (range: 36 to 43 weeks) and birth weight of 3.263kg (range: 2.530 to 4.005kg). Twenty-nine (54%) newborns were male. Vaginal delivery was more commonly used (74%) than the cesarean section (26%). The PB sample donor median age was 33 years old (range 18 to 66 years old) and 15 (60%) were male.

Absolute counts of WBCs and subpopulations

The total white blood cell (WBC) count was higher in the UCB than in the PB (10.782×10^9 vs. 6.980×10^9 , $p < 0.0001$). The total number of cells from most lineages (neutrophils, eosinophils, monocytes and B cells) were higher in the UCB, while

total T cells, NK cells and total DCs were similar in both groups (Table 2). Among subpopulations, many differences were noted: non-classic monocytes, double positive CD4+CD8 + T cells and double negative CD4-CD8- T cells were in higher counts in the PB than in the UCB (0.051×10^9 vs. 0.024×10^9 , $p < 0.0001$; 0.005×10^9 vs. 0.001×10^9 , $p < 0.0001$; 0.054×10^9 vs. 0.039×10^9 , $p = 0.005$, respectively). However, the pDCs were in lower counts in the PB than in the UCB (0.006×10^9 vs. 0.008×10^9 , $p = 0.03$, Table 3). No significant statistical difference was observed in mDC counts between the groups.

Relative frequencies of WBCs and subpopulations

The proportion of B cells and NK cells were higher in the UCB samples when compared to the PB samples (16% vs. 11%, $p < 0.0001$; 20% vs. 11%, $p < 0.006$, respectively).

In terms of relative frequencies of subpopulations, classic monocytes were the predominant subset, being present in a higher count in the UCB vs. the PB (89% vs. 77% , $p < 0.006 \times 10^9$), respectively. The classic monocytes:non-classic monocytes ratio was 28.3 in the UCB and 7.0 in the PB ($p < 0.0001$).

The T cells CD4+ were more prevalent than the T cells CD8 + in both the PB and the UCB (CD4: CD8 ratio 1.8 and 2.3,




Figure 3–Dot plot graphs of flow cytometry analyses showing gating strategy to monocyte identification. Monocytes have higher size and complexity than lymphocytes, CD45+, CD14+, strong HLA-DR and CD11c (A–E). They were further divided into classic (CD14+CD16-), intermediate (CD14+CD16+) and non-classic (CD14low/CD16+) (F).

respectively), while the T cells CD8+ were more frequent in the PB (31%) than in the UCB (27%, $p = 0.03$).

The NK cells 56dim16bright counts were the predominant subset in both samples (96% and 93%, PB and UCB, respectively). The ratio between the subtypes (NK cell NK 56^{dim}16^{bright}: NK 56^{bright}16⁻) was lower in the UCB (13.7) vs. the PB (24, $p = 0.03$). NK 56^{dim}16^{bright} proportions of the pDC in the UCB, compared to the PB from normal adults

The mDCs were the predominant subtype in both the PB and UCB, being 3 times the number of pDCs in the PB and 1.8 times the number of pDCs in the UCB. However, there was no difference in mDC absolute counts between the two groups. The pDC proportion was 25% in the PB and 36% in the UCB ($p < 0.0001$). The mDC:pDC ratio was 3.0 in the PB vs. 1.8 in the UCB ($p < 0.0001$).

The CD4:CD8 ratio was higher in the UCB (2.3) than in the PB (1.8, $p = 0.01$), and the NK cell NK 56^{dim}16^{bright}:NK 56^{bright}16⁻ ratio was lower in the UCB (13.7) vs. the PB (24, $p = 0.03$). The intermediate monocytes:non-classic monocytes ratio was 28.3 in the UCB and 7.0 in the PB ($p < 0.0001$) (Figure 4).

Discussion

In the present study, we compared concentrations (cells per liter) and frequencies (%) of WBCs and subsets in the

UCB and PB from healthy individuals and observed higher counts and frequencies of the NK 56^{bright}16⁻ NK cells and pDCs and lower counts and frequencies of non-classic monocytes in the UCB.

To the best of our knowledge, this is the first study that compared subsets of the NK (NK 56^{dim}16^{bright} and NK 56^{bright}16⁻) between the UCB and PB. The NK 56^{bright}16⁻ is a more immature NK cell, presenting a more humoral immune response profile, secreting the INF- γ , TNF- α , IL-10, IL-13 and granulocyte-macrophage colony-stimulating factor, rather than the direct cytotoxic effect of the NK 56^{dim}16^{bright}. They usually do not present KIR receptors and present higher expressions of the heterodimer CD94/NKG2A (major inhibitor receptor), which confers a lower alloreactivity than their more mature NK 56^{dim}16^{bright} counterpart.²⁰ Therefore, there are higher counts and higher frequencies of NK 56^{bright}16⁻ NK cells and plasmacytoid dendritic cells in the UCB than in the PB.

Of interest, the monocyte maturation was clearly more evident in the PB than in the UCB samples. The PB showed high proportions of the late phases of monocyte differentiation, such as intermediate and non-classic monocytes, which was also observed by some previous studies.²¹ These populations represent a shift towards higher antigen-presenting activity and they are considered as monocyte-derived DCs²² and are also being related to autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.²³




Figure 4– Concentrations of lymphocytes, CD4 T cells, NK cells, dendritic cells and monocytes and respective subsets in PB and UCB samples.

We found higher counts of pDCs in the UCB than in the PB, corroborating the findings of Prabhu SB *et al.*²¹; the pDC produces the IFN type I, which is related to antiviral response, immune tolerance and anti-tumor immunity through secretion of the type-I IFN and TNF- α .²⁴ Moreover, our group previously demonstrated that grafts with a high pDC content lead to a lower aGVHD and lower mortality risk after the HSCT.¹⁸

The GVHD is a reaction caused in part by donor alloreactive T CD8+ and T cell depletion (*in vivo* or *ex vivo*), which is a common strategy to mitigate this complication.^{25,26} Here we demonstrated

a higher concentration of the T CD8+ in the PB, compared to the UCB, as has been shown in previous studies.^{27–29}

All these findings in the PB: more mature monocytes, a higher concentration of T CD8+ and lower counts of pDC and NK 56^{bright}16⁻, compared to the UCB, might explain the higher incidence of the cGVHD when the PB is used as a stem cell source for the HSCT.³⁰ Conversely, the more tolerogenic profile observed in the UCB, compared to the PB, could explain the lower risk of the cGVHD with similar relapse rates as evidence of the sustained GvL effect.^{5,31,32}

Table 2 – Relative distribution and absolute counts of total leukocytes, neutrophils, eosinophils, monocytes, lymphocytes (T-cells, B cells and NK cells) and dendritic cells in peripheral blood and umbilical cord blood samples.

Cellular population	PB N %	UCB N %	P	PB N $\times 10^9$ /L	UCB N $\times 10^9$ /L	P
WBC				6.98 (4.44–13.9)	10.78 (3.74–17.38)	< .0001
Neutrophils	60% (35–70)	60% (25–78)	NS	4.38 (1.64–9.53)	6.46 (1.51–12.1)	< .0001
Immature Neutrophils	.2% (0–.9)	5% (0–20)	< .0001	.007 (.00–0.43)	.30 (.00–1.52)	< .0001
Eosinophils	2% (2–5.6)	3% (.7–9)	NS	1.53 (.01–.43)	3.38 (.085–.73)	< .0001
Monocytes (total)	5.5% (3–8.4)	9% (2.6–23)	< .0001	.44 (.23–.67)	1.03 (.18–2.58)	< .0001
Lymphocytes (total)	30% (21–55)	26% (12–57)	.052	1.91 (1.49–3.88)	2.75 (.89–4.97)	< .0001
T-cells	75% (55–85)	61% (37–82)	.0001	1.57 (.83–3.09)	1.64 (.55–3.16)	NS
B-cells	11% (7–21)	16% (4–31)	< .0001	.23 (.11–.51)	.43 (.06–1.53)	< .0001
NK cells	11% (2–37)	20% (5–46)	< .006	.27 (.06–.71)	.48 (.14–1.38)	< .0001
Dendritic cells	.33 (.24–.79)	.22 (.07–.76)	< .0001	.024 (.01–.06)	.024 (.016–.08)	NS

PB Peripheral blood, UCB Umbilical cord blood, WBC white blood count, pDCs plasmacytoid dendritic cells, mDCs myeloid dendritic cells.

Table 3 – Relative distribution, absolute counts and ratios of monocytes, T-cells, NK cells and dendritic cells subpopulation.

Cellular population	PB N %*	UCB N %*	P	PB N $\times 10^9$ /L	UCB N $\times 10^9$ /L	P
Monocytes						
Classic (A)	77% (61–86)	89% (75–97)	< .0001	.32 (.17–.57)	.89 (.14–2.38)	< .0001
Intermediate	9% (6–24)	8% (2–22)	.017	.041 (.02–.14)	.074 (.02–.22)	< .0001
Non-classic (B)	11% (6–22)	3% (1–13)	< .0001	.051 (.02–.11)	.024 (.01–.15)	< .0001
(A:B ratio)	7	28.3	< .0001			
T cells						
CD4+	60% (33–85)	68% (47–84)	.001	0.94 (.05–1.88)	1.11 (0.32–2.46)	NS
CD8+	31% (12–60)	27% (13–47)	.03	.45 (.22–1.04)	0.45 (.14–.78)	NS
(CD4:CD8 ratio)	1.8	2.3	.01			
CD4+CD8+	.3% (0–.9)	.1% (0–1.4)	< .0001	.010 (.00–.01)	.001 (.00–.03)	.001
CD4-CD8-	4% (1.4–10)	2.5% (1–5)	< .0001	.054 (.02–.14)	.039 (.01–.10)	.005
NKT cells	.32 (.10–2.34)	.27 (.05–.66)	.07	.032 (.01–.23)	.027 (.01–.06)	.07
NK cells						
CD56 ^{dim} /CD16+(C)	96% (76–99)	93% (72–99)	.03	.26 (.05–.70)	.45 (.01–1.35)	.001
CD56 ^{bright} /CD16-(D)	4% (1.5–24)	7% (1–29)	.03	.01 (.01–.03)	.02 (.01–.19)	< .0001
(C:D ratio)	24	13.7	.03			
Dendritic cells						
pDC	25% (14–41)	36% (14–62)	< .0001	.006 (.003–.02)	.008 (.001–.03)	.03
mDC	75% (59–87)	64% (38–89)	< .0001	.018 (.01–.05)	.015 (.003–.06)	NS
(mDC:pDC ratio)	3	1.8	< .0001			

PB Peripheral blood, UCB Umbilical cord blood, pDCs plasmacytoid dendritic cells, mDCs myeloid dendritic cells.

Our study has limitations, such as small sample size and the use of PB samples without the stimulation of granulocyte colony-stimulating factors, as commonly used for the HSCT, which could change the cells counts and frequencies.

Conclusion

In conclusion, we observed higher counts of NK 56^{bright}16⁻ cells and pDCs and lower counts of non-classic monocytes in the UCB, compared to the PB from healthy individuals. Even though the PB analyzed in this study was not obtained through apheresis, our findings could suggest that the UCB cell profile is more tolerogenic than the PB and this finding might explain the lower incidence and severity of the cGVHD in UCB recipients, compared to other stem cell sources, although maintaining the GvL effect. Future research is needed for a better understanding of immune reconstitution in the HSCT and to explain the differences regarding immune

reconstitution and the GvHD risk, the GvL effect and other clinical outcomes in the HSCT among different stem cell sources.

Authorship statement

M.C.R.B., V.C.M, M.V.G. and C.A.R. designed the research, performed research, analyzed data and wrote the paper; V.C.M, M.V.G. and C.A.R. performed statistical analysis; A. M. J. and C. A. A provided cord blood samples, M.C.R.B., M.Y. and M.V. G. performed flow cytometry analysis, critical review and revised the manuscript. All authors drafted and approved the manuscript and agreed with its submission.

Financial Disclosure Statement

The authors have nothing to disclose.

Conflicts of interest

There are no conflicts of interest to report.

Acknowledgments

M.C.R.B. was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, No. 001). V.C.M. was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq Process No. 141575/2018-2).

REFERENCES

- Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. *Biol Blood Marrow Transplant* [Internet]. 2011;17(11):1688–97. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1083879111002072>.
- van den Brink MRM, Velardi E, Perales M-A. Immune reconstitution following stem cell transplantation. *Hematology* [Internet]. 2015;2015(1):215–9. Available from: <http://www.asheducationbook.org/cgi/doi/10.1182/asheducation-2015.1.215>.
- Gluckman E, Broxmeyer HE, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med* [Internet]. 1989;321(17):1174–8. Available from: <https://doi.org/10.1056/NEJM198910263211707>.
- Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang M-J, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. *N Engl J Med* [Internet]. 2004;351(22):2265–75. [cited 2018 Oct 20]. Available from: www.nejm.org.
- Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. *N Engl J Med* [Internet]. 2004;351(22):2276–85. [cited 2018 Oct 20]. Available from: www.nejm.org.
- Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, et al. Immune reconstitution after double umbilical cord blood ssstem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* [Internet]. 2012;18(4):565–74. [cited 2018 Oct 20]. Available from: https://ac.els-cdn.com/S108387911100351X/1-s2.0-S108387911100351X-main.pdf?_tid=a0dc3e79-7ab8-4692-9227-0d6341f72a39&acd-nat=1540088113_ffb39ce3d3966ac3de8dbd84094cf5a6.
- Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. *Br J Haematol* [Internet]. 2011;155(2):218–34. Available from: <http://doi.wiley.com/10.1111/j.1365-2141.2011.08822.x>.
- Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. *J Immunol* [Internet]. 2005;175(3):1373–81. [cited 2018 Oct 8]. Available from: <http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.175.3.1373>.
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature* [Internet]. 1998;392(6673):245–52. Available from: <http://www.nature.com/articles/32588>.
- Darrasse-Jeze G, Deroubaix S, Mouquet H, Vitorica GD, Eisenreich T, Yao K, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. *J Exp Med* [Internet]. 2009;206(9):1853–62. [cited 2018 Oct 21]. Available from: www.jem.org/cgi/doi/10.1084/jem.20090746.
- Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. *Immunology* [Internet]. 2013;140(1):22–30. Available from: <http://doi.wiley.com/10.1111/imm.12117>.
- Lau J, Sartor M, Bradstock KF, Vuckovic S, Munster DJ, Hart DNJ. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease. *Transplantation* [Internet]. 2007;83(7):839–46. [cited 2018 Oct 9]. Available from: <https://insights.ovid.com/crossref?an=00007890-200704150-00002>.
- Waller EK, Logan BR, Harris WAC, Devine SM, Porter DL, Mineishi S, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. *J Clin Oncol* [Internet]. 2014;32(22):2365–72. [cited 2018 Oct 9]. Available from: <http://ascopubs.org/doi/10.1200/JCO.2013.54.4577>.
- Gonçalves MV, Yamamoto M, Kimura EYS, Colturato VAR, de Souza MP, Mauad M, et al. Low counts of plasmacytoid dendritic cells after engraftment are associated with high early mortality after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* [Internet]. 2015;21(7):1223–9. [cited 2018 Oct 10]. Available 492 from: <https://doi.org/10.1016/j.bbmt.2015.03.010>.
- Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. *Adv Cancer Res* [Internet]. 2008;101(08):277–348. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0065230X08004089>.
- Caligiuri MA. Human natural killer cells. *Blood* [Internet]. 2008;112(3):461–9. Available from: <http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-09-077438>.
- Ruggeri L, Capanni M, Mancusi A, Perruccio K, Burchielli E, Martelli MF, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. *Blood* [Internet]. 1999;94(1):333 LP–339. Available from: <http://www.bloodjournal.org/content/94/1/333.abstract>.
- Gonçalves MV, Yamamoto M, Kimura EYS, Renzi Colturato VA, Ikoma MV, Mauad M, et al. Low counts of natural killer cells CD56 bright CD16 negative after engraftment are associated with worse survival in patients receiving allogeneic hematopoietic stem cell transplantation. Vescovi Gonçalves M, editor. *Blood* [Internet]. 2013;122(21):4625 LP–4625. Available from: <http://www.bloodjournal.org/content/122/21/4625.abstract>.
- Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socié G, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. *Leukemia* [Internet]. 2009;23(3):492–500. [cited 2018 Oct 21]. Available from: <http://www.nature.com/articles/leu2008365>.
- Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56 bright natural killer (NK) cells: an important NK cell subset. *Immunology* [Internet]. 2009 Apr;126(4):458–65. Available from: <http://doi.wiley.com/10.1111/j.1365-2567.2008.03027.x>.
- Prabhu SB, Rathore DK, Nair D, Chaudhary A, Raza S, Kanodia P, et al. Comparison of human neonatal and adult blood leukocyte subset composition phenotypes. Yu XG, editor. *PLoS One* [Internet]. 2016;11(9):e0162242. Available from: <https://dx.plos.org/10.1371/journal.pone.0162242>.
- Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. Phenotype, function, and differentiation potential of human monocyte subsets. *PLoS One* [Internet]. 2017;12(4):e0176460. Available from: <https://doi.org/10.1371/journal.pone.0176460>.
- Yang J, Zhang L, Yu C, Yang X-F, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte

- as biomarker for inflammatory diseases. *Biomark Res* [Internet]. 2014;2(1):1. Available from: <https://doi.org/10.1186/2050-7771-2-1>.
24. Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. *Eur J Immunol*. 2010;40(10):2667–76.
 25. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, et al. CCR2 is required for CD8-induced graft-versus-host disease. *Blood* [Internet]. 2005;106(9). 3322 LP–3330. Available from: <http://www.bloodjournal.org/content/106/9/3322.abstract>.
 26. Busca A, Aversa F. In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. *Expert Opin Biol Ther* [Internet]. 2017;17(11):1–15. Available from: <https://doi.org/10.1080/14712598.2017.1369949>.
 27. Beck R, Lam-Po-Tang PR. Comparison of cord blood and adult blood lymphocyte normal ranges: a possible explanation for decreased severity of graft versus host disease after cord blood transplantation. *Immunol Cell Biol* [Internet]. 1994;72(5):440–4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7835989>.
 28. D'Arena G, Musto P, Cascavilla N, Di Giorgio G, Fusilli S, Zendoli F, et al. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. *Haematologica* [Internet]. 1998;83(3):197–203. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9573672>.
 29. Szabolcs P, Park K-D, Reese M, Marti L, Broadwater G, Kurtzberg J. Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. *Exp Hematol* [Internet]. 2003;31(8):708–14. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0301472X03001607>.
 30. Rodrigues CA, Rocha V, Dreger P, Brunstein C, Sengeloev H, Finke J, et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. *Haematologica* [Internet]. 2014;99(2). 370 LP–377. Available from: <http://www.haematologica.org/content/99/2/370.abstract>.
 31. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. *Lancet Oncol* [Internet]. 2010;11(7):653–60. [cited 2018 Oct 20]. Available from: www.thelancet.com/oncology.
 32. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, DeFor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. *Blood* [Internet]. 2010;116(22):4693–9. [cited 2018 Oct 20]. Available from: www.bloodjournal.org.